Genexine, Inc. (095700.KQ)

KRW 5590.0

(-3.79%)

Gross Profit Summary of Genexine, Inc.

Genexine, Inc.'s latest annual gross profit in 2023 was 387.48 Million KRW , down -154.73% from previous year.
Genexine, Inc.'s latest quarterly gross profit in 2024 Q2 was -1.33 Billion KRW , up 87.05% from previous quarter.
Genexine, Inc. reported a annual gross profit of 7.3 Billion KRW in annual gross profit 2022, down -74.94% from previous year.
Genexine, Inc. reported a annual gross profit of 29.15 Billion KRW in annual gross profit 2021, up 205.22% from previous year.
Genexine, Inc. reported a quarterly gross profit of -1.41 Billion KRW for 2024 Q1, down -54.15% from previous quarter.
Genexine, Inc. reported a quarterly gross profit of -889.27 Million KRW for 2023 Q2, up 0.66% from previous quarter.

Annual Gross Profit Chart of Genexine, Inc. (2023 - 2012)

Historical Annual Gross Profit of Genexine, Inc. (2023 - 2012)

Year	Gross Profit	Gross Profit Growth
2023	387.48 Million KRW	-154.73%
2022	7.3 Billion KRW	-74.94%
2021	29.15 Billion KRW	205.22%
2020	9.55 Billion KRW	71.69%
2019	5.56 Billion KRW	30.21%
2018	4.27 Billion KRW	-74.93%
2017	17.04 Billion KRW	197.06%
2016	5.73 Billion KRW	-76.17%
2015	24.07 Billion KRW	0.0%
2012	5.35 Billion KRW	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q2	-1.33 Billion KRW	87.05%
2024 Q1	-1.41 Billion KRW	-54.15%
2023 Q2	-889.27 Million KRW	0.66%
2023 FY	-3.99 Billion KRW	-154.73%
2023 Q4	-915.29 Million KRW	26.69%
2023 Q3	-1.24 Billion KRW	-40.4%
2023 Q1	-895.18 Million KRW	-79.15%
2022 Q4	-499.68 Million KRW	12.55%
2022 FY	7.3 Billion KRW	-74.94%
2022 Q1	6.64 Billion KRW	4278.02%
2022 Q3	-571.4 Million KRW	27.44%
2022 Q2	-787.5 Million KRW	-111.86%
2021 Q1	29.77 Billion KRW	1077.93%
2021 FY	29.15 Billion KRW	205.22%
2021 Q2	125.14 Million KRW	-99.58%
2021 Q3	-596.52 Million KRW	-576.67%
2021 Q4	-158.98 Million KRW	73.35%
2020 Q3	231.05 Million KRW	-75.08%
2020 FY	9.55 Billion KRW	71.69%
2020 Q2	927.27 Million KRW	-84.73%
2020 Q4	2.52 Billion KRW	994.18%
2020 Q1	6.07 Billion KRW	417.82%
2019 Q2	2.24 Billion KRW	463.03%
2019 FY	5.56 Billion KRW	30.21%
2019 Q4	1.17 Billion KRW	-59.31%
2019 Q3	2.88 Billion KRW	28.36%
2019 Q1	398.8 Million KRW	0.0%
2018 FY	4.27 Billion KRW	-74.93%
2017 FY	17.04 Billion KRW	197.06%
2016 FY	5.73 Billion KRW	-76.17%
2015 FY	24.07 Billion KRW	0.0%
2013 Q3	972.28 Million KRW	0.0%
2012 Q3	756.76 Million KRW	0.0%
2012 FY	5.35 Billion KRW	0.0%

Peer Gross Profit Comparison of Genexine, Inc.

Name	Gross Profit	Gross Profit Difference
HLB Co., Ltd.	-6.01 Billion KRW	106.445%
iNtRON Biotechnology, Inc.	4.56 Billion KRW	91.504%
BINEX Co., Ltd.	56.65 Billion KRW	99.316%
Bioneer Corporation	199.25 Billion KRW	99.806%
Anterogen.Co.,Ltd.	2.21 Billion KRW	82.494%
MEDIPOST Co., Ltd.	40.18 Billion KRW	99.036%
CrystalGenomics, Inc.	1.45 Billion KRW	73.405%
Helixmith Co., Ltd	2.12 Billion KRW	81.738%
Chabiotech Co.,Ltd.	255.19 Billion KRW	99.848%
Medy-Tox Inc.	128.16 Billion KRW	99.698%
Peptron, Inc.	1.14 Billion KRW	66.027%
Amicogen, Inc.	51.51 Billion KRW	99.248%
HLB Therapeutics Co.,Ltd.	6.69 Billion KRW	94.212%
LegoChem Biosciences, Inc.	17.79 Billion KRW	97.823%
ALTEOGEN Inc.	31.19 Billion KRW	98.758%
PharmaResearch Co., Ltd.	182.25 Billion KRW	99.787%
SillaJen, Inc.	1.45 Billion KRW	73.401%
JETEMA, Co., Ltd.	26.58 Billion KRW	98.542%
OliX Pharmaceuticals,Inc	14.42 Billion KRW	97.313%
Genomictree Inc.	-1.03 Billion KRW	137.309%
MedPacto, Inc.	-1.83 Billion KRW	121.143%
D&D Pharmatech	18.67 Billion KRW	97.925%
EASY BIO,Inc.	50.88 Billion KRW	99.239%
GI Innovation, Inc.	1.98 Billion KRW	80.523%